We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00429520
Recruitment Status : Completed
First Posted : January 31, 2007
Last Update Posted : February 7, 2008
Information provided by:
Merz Pharmaceuticals GmbH

January 30, 2007
January 31, 2007
February 7, 2008
December 2005
Not Provided
Severity rating scale assessed by independent rater
Same as current
Complete list of historical versions of study NCT00429520 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds
Prospective, Multicentre, Not Controlled Clinical Study to Investigate Efficacy and Tolerability of the Hyaluronic Acid Filler IMD1 Basic After Single Bilateral Injection for Correction of Nasolabial Folds (NLF)
Volunteers receive one injection IMD1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.
Not Provided
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Nasolabial Folds
Drug: Hyaluronic acid filler/IMD1 basic
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2006
Not Provided

Inclusion Criteria:

  • main inclusion criteria: severity rating scale grade 3 or 4

Exclusion Criteria:

  • main exclusion criterion: other nasolabial fold corrections within 6 months prior to study entry
Sexes Eligible for Study: All
30 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
MRZ 90026-0423/1
Not Provided
Not Provided
Not Provided
Not Provided
Merz Pharmaceuticals GmbH
Not Provided
Principal Investigator: Johannes Reinmüller, MD Klinik am Sonnenberg, Wiesbaden, Germany
Merz Pharmaceuticals GmbH
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP